16434975	Disease	Gene	D011471	7157	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] The R273H @GeneTgt$ p53 @/GeneTgt$ mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7 . Mutations in @GeneTgt$ p53 @/GeneTgt$ occur at a rate of approximately 70 % in hormone-refractory @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( CaP ) , suggesting that @GeneTgt$ p53 @/GeneTgt$ mutations facilitate the progression of CaP to androgen-independent ( AI ) growth . We have previously reported that transfection of @GeneTgt$ p53 @/GeneTgt$ gain of function mutant alleles into LNCaP , an androgen-sensitive cell line , allows for AI growth of LNCaP in vitro . We herein confirm the in vivo relevance of those findings by demonstrating that the R273H p53 mutation ( p53(R273H ) ) facilitates AI growth in castrated nude mice . In addition , we demonstrate that H2 relaxin is responsible for facilitating @GeneTgt$ p53(R273H)-mediated @/GeneTgt$ AI CaP. H2 relaxin is overexpressed in the LNCaP-R273H subline . Downregulation of H2 relaxin expression results in significant inhibition of AI growth , whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth . Inhibition of AI growth was also achieved by blocking expression of LGR7 , the cognate receptor of H2 relaxin . Chromatin immunoprecipitation analysis was used to demonstrate that @GeneTgt$ p53(R273H @/GeneTgt$ ) binds directly to the relaxin promoter , further confirming a role for H2 relaxin signaling in @GeneTgt$ p53(R273H)-mediated @/GeneTgt$ AI CaP. Lastly , we used a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific antigen via an androgen receptor-mediated pathway .	5 5 2|5 5 2|5 7 7 7 10 10 7 12 10 15 15 7 17 15 19 17 19 24 24 24 19 7 31 29 27|28 27 27|28 31 34 34 31 38 37 38 34 41 41 34|39|41 34|39|41 34|41 34|39|41 45 41 45 31 31 53 52|46 52 52|46 53 48 55 53 57 55 63 63 61 59 61 55 31 71 71 71 71 90 90 77 77|74 77 77|74 73 81 81 81 77 83 73 83 88 88 88 83 73 71 93 93 90 95 93 97 90 71 102 102 102 106 106 104 102 109 109 106 111 102 121 116 116 116 121 118 116 118 118 111 123 121 127 127 127 123 102 130 133 133 133 133 138 136 138 138 133 140 138 146|140 146 146|140 146 146 146 140 148 138 152 152 152 148 133 160 159 159 159 155 160 163 163 160 166 166 163 160 178 178 174 174 174 174 169 177 177 169 160 180 178 160 188 185 185 182 188 188 188 190 188 190 193 191 193 197 197 193 200 200 197 188 204 204 206 206 206 208 206 213 209|213 213 209|213 210 208 213 218 218 218 213 213 221 206 223 221 227 227 227 223 232 227|232 232 227|232 232 227 236 236 236 221 240 240 240 236 242 236 247 245 247 247 242 249 247 252 252 249 257 257 256 257 247 206	Association
12783936	Disease	Gene	D011471	5444	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ PON1 @/GeneTgt$ ? [SEP] New @GeneTgt$ paraoxonase 1 @/GeneTgt$ polymorphism I102V and the risk of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in Finnish men . BACKGROUND : Human serum paraoxonase eliminates carcinogenic lipid-soluble radicals . Because expression of the main human paraoxonase gene @GeneTgt$ PON1 @/GeneTgt$ varies widely in humans , certain @GeneTgt$ PON1 @/GeneTgt$ polymorphisms might be associated with increased risks of cancer . We sought new functional mutations in @GeneTgt$ PON1 @/GeneTgt$ and determined whether known or new @GeneTgt$ PON1 @/GeneTgt$ mutations were associated with the risk for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in a prospective , random , population-based sample of Finnish men and in a case-control study . METHODS : Serum paraoxonase activity was measured in 835 healthy men in the Kuopio Ischaemic Heart Disease Risk Factor Study . @GeneTgt$ PON1 @/GeneTgt$ mutations were identified by hierarchical phenotype-targeted sequencing in DNAs from the 100 men with the lowest paraoxonase activity in this cohort , and 1595 men in the cohort were genotyped for @GeneTgt$ PON1 @/GeneTgt$ mutations by restriction fragment length polymorphism . Multivariable analysis was used to investigate the association of known and new @GeneTgt$ PON1 @/GeneTgt$ mutations with incident @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in 1569 cancer-free men in the cohort followed for 9 - 14 years . In a case-control study of Finnish men , the association of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ with the @GeneTgt$ PON1 @/GeneTgt$ mutation identified in the cohort study was investigated in 69 case patients with familial prostate cancer and 69 unmatched healthy control subjects . RESULTS : We identified a new single-nucleotide @GeneTgt$ PON1 @/GeneTgt$ polymorphism associated with decreased serum paraoxonase activity that caused an isoleucine-->valine change at codon 102 in exon 4 ( I102V ) . Of the 1569 men cancer-free at baseline , 56 ( 3.6 % ) were carriers of the I102V mutation . After adjusting for age and cholesterol-lowering medications , the relative risk for developing @DiseaseSrc$ prostate cancer @/DiseaseSrc$ during follow-up was 6.3 ( 95 % confidence interval [ CI ] = 2.1 to 19.2 ) among 102V allele carriers compared with noncarriers . Other @GeneTgt$ PON1 @/GeneTgt$ alleles were not statistically significantly associated with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . In the case-control study , patients with familial prostate cancer were more likely to be carriers of the @GeneTgt$ PON1 @/GeneTgt$ I102V mutation than control subjects ( odds ratio = 4.3 , 95 % CI = 0.9 to 21.5 ) . CONCLUSION : The @GeneTgt$ PON1 @/GeneTgt$ 102V allele appears to be associated with an increased risk for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ .	6 1|6 1|6 6 1|6 6 6 6 9 6 11 8|9|11 8|9|11 9|11 8|9|11 16 16 11 6 20 20 24 24 25 20 28 28 25 25 40 40 38 38 38 38 38 38 37|31 31 37|31 51 40 43 40 51 48 48|44 48 48|44 51 51 51 51 54 54 51 56 54 51 61 61 64 64 61 66 64|65 64 64|65 61 61 71 69 71 71 76|72 76 76|72 78 78 71 81 81 78 83 83|80|81 83|80|81 83|81 83|80|81 93 93 93 88 88 93 93 81 96 96 93 93 101 101 101 93 61 112 112 110 110 112 112 112 116 116 116 112 125 125 125 124 122 124 124 125 116 112 126|129 129 126|129 131 131 131 135 135 135 131 137 135 141 141 141 137 146 146 146 146 141 149 149 146 137 137 153 158 156 156 153 158 131 162 158|162 162 158|162 158 167 167 167 167 158 131 172 174 174 174 176 174 178 176 180 185 180 180 182|185 185 182|185 178 188 188 186|188|185 186|188|185 188|185 186|188|185 194 194 194 188 197 197 194 178 203 202 202 203 198 174 210 210 210 232 213 213 210 213 216 232 218 216|217|218 216|217|218 216|218 216|217|218 225 225 225|220 225 225|220 216 225 230 230 230 226 232 232 236 236 236 232 240 240 240 236 236 246 246 246 246 236 232 250 250 253 250 259 259 259 259|256 259 259|256 253 259 265 265 265 265 260 267 259 270 270 267 272 270 272 275 272 275 278 275 278 250 285 285 285 286 296 288 286 296 296 293 293 290 293 296 296 300 300 300 296 296 303 326 305 303 305 305 305 326 312 312 326 314 312 314|315 314|315 314|315 314|315 319 314 326 326 326 324 326 326 326 328 326 328 326 333 331 330 330 338 338 338 330 326 341 339 326 347 344|347 347 344|347 352 352 352 351 352 352 354 352|354 352|354 352|354 352|354 352 363 363 363 372 372 372 369 369 369 365 372 372 372 375 375 372 381 381 377|381 381 377|381 381 375 384 384 375 387 387 375 387 393 393 392 393 388 393 397 397 394 387 372 401 408 407 403|407 407 403|407 407 408 401 411 411 408 415 415 415 411 417 417|415 417|415 417|415 417|415 408	Association
15863270	Disease	Gene	D011471	60528	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ ELAC2 @/GeneTgt$ ? [SEP] The missense mutations in the candidate @DiseaseSrc$ prostate cancer @/DiseaseSrc$ gene @GeneTgt$ ELAC2 @/GeneTgt$ do not alter enzymatic properties of its product . The candidate @DiseaseSrc$ prostate cancer @/DiseaseSrc$ gene @GeneTgt$ ELAC2 @/GeneTgt$ encodes tRNA 3 ' processing endoribonuclease ( tRNase ZL ) . We produced recombinant human tRNase ZL 's , which contain one to three amino-acid substitutions from three missense mutations ( Ser217Leu , Ala541Thr , and Arg781His ) that are associated with the occurrence of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . These enzymes were examined for the pre-tRNA cleavage and the RNase 65 activity . We did not observe any differences in enzymatic properties such as Km and k(cat ) values between the wild-type tRNase ZL and its variants . We conclude that there is no causality between the enzymatic properties of tRNase ZL and the @DiseaseSrc$ prostate cancer @/DiseaseSrc$ .	3 3 15 11 11 11 11|6 11|6 11 11|6 11 8|3 3 8|3 15 15 15 17 15 20 20 17 15 30 30 25|30 25|30 30 25|30 30 32|27 32 32|27 32 32 37 37 37 33 40 40 37 40 32 46 46 49 49 46 49 50 49 54 49 59 59 59 59 54 63 63 63 59 65 63 65 65 65 65 65 65 74 74 63 77 77 74 79 77|78|79 77|78|79 77|79 77|78|79 46 85 87 87 87 91 91 91 87 91 96 96 96 91 87 101 101 101 101 103 101 106 106 103 109 107 106 109 109 111 109 117 117 117 113 117 117 121 117 101 124 124 127 127 124 129 127 133 133 133 129 135 136 133 136 139 138|139|136 138|139|136 139|136 138|139|136 124	Association
18288683	Disease	Gene	D011471	79728	False	1	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ PALB2 @/GeneTgt$ ? [SEP] Analysis of the gene coding for the BRCA2-interacting protein @GeneTgt$ PALB2 @/GeneTgt$ in hereditary prostate cancer . BACKGROUND : The genetic basis of susceptibility to @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( PRCA ) remains elusive . Mutations in BRCA2 have been associated with increased @DiseaseSrc$ prostate cancer @/DiseaseSrc$ risk and account for around 2 % of young onset ( < 56 years ) @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cases . @GeneTgt$ PALB2 @/GeneTgt$ is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures . This functional relationship made @GeneTgt$ PALB2 @/GeneTgt$ a candidate PRCA susceptibility gene . METHODS : We sequenced @GeneTgt$ PALB2 @/GeneTgt$ in probands from 95 PRCA families , 77 of which had two or more cases of early onset PRCA ( age at diagnosis < 55 years ) , and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA . RESULTS : Two previously unreported variants , K18R and V925L were identified , neither of which is in a known @GeneTgt$ PALB2 @/GeneTgt$ functional domain and both of which are unlikely to be pathogenic . No truncating mutations were identified . CONCLUSIONS : These results indicate that deleterious @GeneTgt$ PALB2 @/GeneTgt$ mutations are unlikely to play a significant role in hereditary prostate cancer .	1 4 4 1 4 10 10 10 10 9|5 5 9|5 15 15 15 5 1 18 18 22 22 32 24 22 26 25|26|24 25|26|24 26|24 25|26|24 30 26 30 18 32 32 41 38 36 41 41 41 47 47 43|47 43|47 47 43|47 41 47 47 53 52 53 49 56 56 53 60 60 60 53 60 59|65 59|65 65 59|65 53 41 68|78 78 68|78 78 78 74 78 78 78 78 78 80 83 83 83 78 85 83 83 88 83 91 91 88 94 94 91 78 99 99 100 100 107|100 107 107|100 107 107 107 107 100 100 113 113 113 113 113 113 113 117 113 121 121 121 117 117 126 125 123 117 130 127 127 126 134 133 134 130 136 134 138 136 138 141 136 136 113 113 147 147 148 113 150 148 154 153 154 150 150 160 156 156 160 150 162 160 148 165 165 170 169 170 176 170 170 172 172 176 165 176 188 180 178 188 188 188 188 188|184 188 188|184 188 176 188 194 192 190 194 176 197 197 194 176 202 202 204 204 204 204 206 206 209 210 206 217 215 215|212 215 215|212 217 217 210 219 217 222 222 219 226 226 226 219 206	Association
12949798	Disease	Gene	D011471	60528	True	0	What is [EMU_PC] between @DiseaseSrc$ prostatic cancer @/DiseaseSrc$ and @GeneTgt$ ELAC2 @/GeneTgt$ ? [SEP] Ser217Leu polymorphism of the @GeneTgt$ HPC2/ELAC2 @/GeneTgt$ gene associated with @DiseaseSrc$ prostatic cancer @/DiseaseSrc$ risk in Japanese men . The @GeneTgt$ HPC2/ELAC2 @/GeneTgt$ gene may be associated with hereditary/familial prostate cancer ( PCa ) . Two common missense variants ( Ser217Leu and Ala541Thr ) have been reported in the gene . We performed mutational , allelotyping and expression analyses and a molecular epidemiological study to clarify the relations between this gene and prostatic diseases , including PCa and benign prostatic hyperplasia ( BPH ) in Japanese men . We screened for mutations in 109 patients with PCa including 11 patients from 1 hereditary and 9 familial PCa . Loss of heterozygosity and expression were analyzed . An epidemiological study was done in sporadic PCa ( n=98 ) and BPH ( n=143 ) using 1 novel ( Ser627Leu ) and 2 previously described polymorphisms of the @GeneTgt$ HPC2/ELAC2 @/GeneTgt$ gene . Somatic or germline mutations were not confirmed in any cases of PCa . Loss of heterozygosity at 2 microsatellites , D17S1289 and D17S520 , was detected in 1 of 38 and 1 of 35 cases , respectively . Expression analysis revealed decreased or absent mRNA expression in 6 of 38 tumors . Epidemiologic analysis showed that a Leu allele at codon 217 was significantly more frequent in patients with PCa than in controls ( 10.2 % vs. 3.5 % , odds ratio = 3.11 ; 95 % confidence interval , 1.22 - 7.90 ) . At codon 541 , all patients with PCa or BPH and all control subjects had the Ala/Ala genotype . At codon 627 , the incidence of the Leu variant was slightly , but not significantly , higher in patients with BPH than in controls ( 7.0 % vs. 2.8 % , odds ratio = 2.59 , 95 % confidence interval , 0.94 - 7.13 , not statistically significant ) . We concluded that germline/somatic mutations of @GeneTgt$ HPC2/ELAC2 @/GeneTgt$ are uncommon in PCa . Similarly , allelic imbalances at the gene locus and changes in expression are rare . Although no difference in allele frequency at Ser217Leu between patients with PCa and controls has been reported in a Western population , this polymorphism is a potential indicator of PCa risk in Japanese men and it should be examined in other ethnic groups .	2 2 7 7 4|7 7 4|7 2 7 13 8|13 8|13 13 8|13 8 16 16 13 2 23 20|23 23 20|23 26 26 26 26 30 30 30 26 32 30 32 26 39 39 39 47 41 39 41 41 41 47 47 47 50 50 47 47 53 53 59 54 54 56 56 53 59 64 64 64 59 66 53 68 66 71 71 68 71 74 71 74 77 71 77 81 81 77 83 81 83 87 87 77 53 90 90 92 90 95 95 92 97 95 100 100 97 103 103 100 103 107 107 103 90 115 111 109 111 111 115 115 115 119 119 121 121 121 124 124 121 126 124 126 124 124 131 129 131 121 135 133 137 135 137 135 135 142 135 135 148 148 148|145 148 148|145 143 121 151 151 151 157 157 157 151 160 160 157 162 160 157 176 166 164 169 169 164 169 169 171 171 169 176 176 178 176 180 178 178 178 185 185 182 178 176 176 190 191 191 196 192 192 196 191 198 196 201 201 198 191 204 205 205 216 209 209 216 211 209 211 216 215 216 205 218 216 220 218 223 223 216 226 226 223 226 229 226 233 232 233 226 233 233 239 239 239 233 239 243 243 239 239 205 247 260 247 260 251 260 253 251 253 253 251 259 259 251 260 263 263 260 260 266 276 266 276 270 276 274 274 274 270 276 282 282 279 280 282 282 282 284 282 286 284 289 289 282 292 292 289 292 295 292 292 298 292 298 299 299 305 305 305 292 305 305 307 305 309 313 313 282 282 282 317 317 325 320 325 322 320|321 320 320|321 325 317 327 325 317 343 343 333 343 337 337 337 333 337 337 341 339 343 343 343 361 347 361 350 350 347 352 350 354 352 356 354 354 354 361 361 372 365 365 365 361 372 368 372 372 372 372 372 375 375 372 378 378 375 372 383 383 383 372 387 387 387 383 383	Association
16282370	Disease	Gene	D011471	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] Stress kinase signaling regulates @GeneTgt$ androgen receptor @/GeneTgt$ phosphorylation , transcription , and localization . Activation of signal transduction kinase cascades is known to alter @GeneTgt$ androgen receptor @/GeneTgt$ ( @GeneTgt$ AR @/GeneTgt$ ) activity , but the molecular mechanisms are still poorly defined . Here we show that stress kinase signaling regulates Ser 650 phosphorylation and @GeneTgt$ AR @/GeneTgt$ nuclear export . In LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells , activation of either MAPK kinase ( MKK ) 4:c-Jun N-terminal kinase ( JNK ) or MKK6:p38 signaling pathways increased Ser 650 phosphorylation , whereas pharmacologic inhibition of JNK or p38 signaling led to a reduction of @GeneTgt$ AR @/GeneTgt$ Ser 650 phosphorylation . Both p38alpha and JNK1 phosphorylated Ser 650 in vitro . Small interfering RNA-mediated knockdown of either MKK4 or MKK6 increased endogenous prostate-specific antigen ( PSA ) transcript levels , and this increase was blocked by either bicalutamide or @GeneTgt$ AR @/GeneTgt$ small interfering RNA . Stress kinase inhibition of PSA transcription is , therefore , dependent on the @GeneTgt$ AR @/GeneTgt$ . Similar experiments involving either activation or inhibition of MAPK/ERK kinase : ERK signaling had little effect on Ser 650 phosphorylation or PSA mRNA levels . Ser 650 is proximal to the DNA binding domain that contains a nuclear export signal . Mutation of Ser 650 to alanine reduced nuclear export of the @GeneTgt$ AR @/GeneTgt$ , whereas mutation of Ser 650 to the phosphomimetic amino acid aspartate restored @GeneTgt$ AR @/GeneTgt$ nuclear export . Pharmacologic inhibition of stress kinase signaling reduced wild-type @GeneTgt$ AR @/GeneTgt$ nuclear export equivalent to the S650A mutant without affecting nuclear export of the S650D mutant . Our data suggest that stress kinase signaling and nuclear export regulate @GeneTgt$ AR @/GeneTgt$ transcriptional activity .	3 3 4 4 8|4 8|4 8 8|4 4 8 8 8 8 8 4 23 21 21 21 21 16 23 23 25 23 33|25|26 33|25|26 33|26 33|25|26 30 33|27 33 33|27 30 25 23 23 38 38 42 42 42 42 23 23 48 48 48 53 52 52 53 48 56 56 53 56 61|57 61 61|57 61 56 48 69 69 65|69 65|69 69 65|69 89 89 89 77 75 75 77 77 71 77 81 81 77 83 81 83 77 88 88 77 89 92 92 89 89 89 96 102 98 96 98 98 98 89 105 105 102 111 111|104 111 111|104 111 111 105 89 116 119 116 116 119 119 123 123 119 119 126 134 128 126 131 131 128 131 131 134 137 137 142 139 142 142 142 134 134 134 146 148 148 134 151 151 148 151 156|152 156 156|152 156 151 151 134 161 162 170 165 165 162 170 170 170 170 170 173 173 170|172 170 170|172 170 178 190 178 181 179 181 181 186 186 183 178 189 190 190 192 190 196 196 196 192 196 199 200 196 190 205 202 205 205 210 210 210 210 205 212 210 216 216 216 212 205 224 220 218 220 223 218 224 226 224 229 229 226|228 226 226|228 224 243 243 235 233 235 242 242 242 242 242 233 224 242|247 247 242|247 247 243 224 252 257 256 256 256 252 257 263 258|262 262 258|262 262 263 257 267 267 267 263 269 257 271 269 275 275 275 271 257 279 280 280 288 284 284 288 284 287 284 280 288|292 292 288|292 292 288 280	Association
17502119	Disease	Gene	D011471	472	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] @GeneTgt$ ATM @/GeneTgt$ missense variant P1054R predisposes to @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . BACKGROUND : @DiseaseSrc$ Prostate cancer @/DiseaseSrc$ is associated with defective DNA strand break repair after DNA damage leading to genetic instability and @DiseaseSrc$ prostate cancer @/DiseaseSrc$ progression . The @GeneTgt$ ATM ( ataxia-telangiectasia mutated ) @/GeneTgt$ gene product is known to play an important role in cell cycle regulation and maintenance of genomic integrity . We investigated whether the prevalence of the @GeneTgt$ ATM @/GeneTgt$ missense substitution P1054R is increased in a hospital-based series of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients and whether carriers are at increased risk for treatment-related side effects . MATERIALS AND METHODS : A consecutive series of 261 patients treated for early-stage @DiseaseSrc$ prostate cancer @/DiseaseSrc$ with I-125 brachytherapy ( permanent seed implantation ) between 10/2000 and 04/2006 at our institution and a comparison group of 460 male control individuals were screened for the presence of the P1054R variant . Outcome of therapy regarding morbidity was assessed prospectively and compared between carriers vs. non-carriers with the International Prostate Symptom Score ( IPSS ) , a Quality-of-Life-index ( QoL ) and the International Index of Erectile Function ( IIEF-15 ) with its subgroups ( IIEF-5 and EF ) . RESULTS : The proportion of carriers of the P1054R variant was significantly higher among @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients than in the general population ( 25 out of 261 vs. 22 out of 460 ; OR 2.1 ; 95 % CI 1.2 - 3.8 , p<0.01 ) . A subgroup of the carriers additionally harboured the @GeneTgt$ ATM @/GeneTgt$ missense variant F858L that was associated with a similar risk ( OR=2.2 ; 95 % CI 1.1 - 4.6 ; p=0.03 ) . After a mean follow-up of 18 months there were no statistically significant differences regarding IPSS ( p=0.48 ) , QoL ( p=0.61 ) , IIEF-15 score ( p=0.78 ) , IIEF-5 score ( p=0.83 ) , and EF score ( p=0.80 ) , respectively . CONCLUSIONS : The @GeneTgt$ ATM @/GeneTgt$ missense variant P1054R confers an about twofold increased risk for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in our series . The subgroup of patients with the second-site variant F858L is not at significantly higher risk . After 18 months , there was no evidence for an increased adverse radiotherapy response in P1054R carriers .	0|5 5 0|5 5 5 6 6 8 8|6 8|6 8|6 8|6 6 14 14 15|16|20 15|16|20 16|20 15|16|20 20 14 26 26 26 26 26 20 29 29 26 20 33 33 30 33 38|32 38|32 38 38|32 33 20 43 42|52|50 42|52|50 42|52|50 42|52|50 42|52|50 50|52 42|52|50 50 43 52 52 54 52 57 57 54 61 61 61 54 61 61 66 66 61 52 70 70 82 73 82 79 79 79|75 79 79|75 79 73 79 82 70 86 86 86 82 91 86|91 86|91 91 86|91 86 82 98 98 98 98 98 82 102 102 102 98 70 106 106 106 106 112 112 147 115 115 112 115 119 119 116|118|119 116|118|119 116|119 116|118|119 124 124 119 128 128 128 124 128 131 119 131 131 136 136 131 131 140 140 131 145 145 145 145 140 147 106 150 150 147 154 154 154 150 147 163 159 157 161 159 163 163 163 163 163 168 166 168 168 176 176 176 176 176 170 178 176 178 176 182 176 184 182 184 182 189 189 182 192 192 189 194 189 194 198 198 182 200 198 200 200 200 163 205 205 208 217 210 208 214 214 214 210 217 217 205 222 222|218 222|218 222 222|218 217 227 227 227 227 217 229 244 229 232 230 232 232 237 237 229 229 229 229 244 243 244 217 247 247 244 249 205 205 205 254 259 257 257 254 259 259 265 260|265 265 260|265 265 265 259 268 268 265 272 272 272 268 274 278 278 277 278 283 281 281 278 283 272 283 259 290 290 290 295 293 293 290 295 295 299 298 299 295 301 299 303 301 303 301 301 308 306 308 301 312 301 314 312 314 301 318 301 320 318 320 301 301 325 301 327 325 327 301 295 295 332 332 339 339|334 339 339|334 339 339 340 332 345 344 344 345 340 347 347|345 347|345 347|345 347|345 352 352 340 332 357 370 359 357 364 364 364 364 359 370 370 370 369 370 370 370 374 374 377 377 377 377 379 377 385 385 385 385 385 379 388 388 385 377	Association
16963262	Disease	Gene	D011471	4292	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ MLH1 @/GeneTgt$ ? [SEP] Identification of germline @GeneTgt$ MLH1 @/GeneTgt$ alterations in familial prostate cancer . Several linkage and loss of heterozygosity ( LOH ) analyses suggest that the region 3p21-p26 , which is a chromosomal location of @GeneTgt$ MLH1 @/GeneTgt$ , could harbour a susceptibility gene for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( PRCA ) . Furthermore , in a recent candidate single nucleotide polymorphism ( SNP ) analysis the I219V variation of the @GeneTgt$ MLH1 @/GeneTgt$ gene was associated with PRCA . Microsatellite instability ( MSI ) and germ-line @GeneTgt$ MLH1 @/GeneTgt$ mutations were originally demonstrated in hereditary non-polyposis colorectal cancer ( HNPCC ) but MSI and loss of @GeneTgt$ MLH1 @/GeneTgt$ function have also been detected in PRCA . To assess the contribution of @GeneTgt$ MLH1 @/GeneTgt$ germline mutations to the development of PRCA in Finland different approaches were used . First , the samples from 11 PRCA-colon cancer patients were screened for @GeneTgt$ MLH1 @/GeneTgt$ , MSH2 and MSH6 protein expression by immunohistochemistry ( IHC ) . IHC revealed one patient with a putative @GeneTgt$ MLH1 @/GeneTgt$ aberration and sequencing of this sample revealed five sequence variants including two missense variants P434L and I219V . Second , the samples from Finnish hereditary prostate cancer ( HPC ) families were used for the screening of @GeneTgt$ MLH1 @/GeneTgt$ mutations which produced twelve @GeneTgt$ MLH1 @/GeneTgt$ sequence variants including two missense mutations , I219V , as in the PRCA-colon cancer patient , and V647 M . P434L and V647 were both novel , rare variants . Carrier frequencies of the I219V mutation were compared between hereditary prostate cancer ( HPC ) patients , unselected PRCA cases , patients with benign prostate hyperplasia and controls , but no differences between the sample groups were found . P434L was not present in this study population and V647 M was a very rare variant found only in one HPC family . According to the present results , @GeneTgt$ MLH1 @/GeneTgt$ does not have a major role in PRCA causation in Finland .	1 6 6 3|6 6 3|6 1 10 10 10 6 1 14 23 14 14 22 22 20 18 20 14 23 39 27 27 39 27 33 33 33 33 27 35 33|34 33 33|34 27 39 23 42 42 39 44 44|42 44|42 44|42 44|42 48 44 48 23 65 65 61 61 61 61 61 61 65 63 61 63 75 68 68 75 73 73 70|73 73 70|73 68 75 75 77 75 75 81 92 83 81 83 81 89 89|86 89 89|86 81 92 92 92 97 97 97 97 92 99 97 99 97 97 97 97 108 104|108 108 104|108 104 112 112 112 92 114 112 92 119 137 121 119 126 126|122 126 126|122 126 121 129 129 121 131 129 135 135 135 129 137 137 137 150 150 143 150 148 148 148 148 143 150 150 152 150|151 150 150|151 152 152 152 152 159 152 161 159 163 161 163 150 168 168 170 168 176 176 176 176|173 176 176|173 170 170 182 181 181 178 168 185 185 182 189 189 189 185 189 190 190 182 209 209 198 209 207 207 207 203 207 205 203 205 198 209 209 212 212 209 216 213|216 216 213|216 212 218 216 223 218|223 223 218|223 223 218 227 227 227 223 227 227 227 236 236 236 236 236 218 236 236 240 236 209 252 244 244 252 249 252 249 249 252 252 255 261 259 259 259 255 261 261 269 265 265 269 267 269 267 261 269 273 273 269 273 269 279 279 279 275 279 279 275 269 285 291 289 289 289 285 291 261 291 296 296 296 296 300 300 300 296 300 303 300 308 308 307 308 296 308 314 314 314 314 309 296 320 316 320 320 326 326 326|321 326 326|321 326 326 326 329 329 326 332 332 329 334 332 326	Association
14691288	Disease	Gene	D011472	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate carcinoma @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] @GeneTgt$ Androgen receptor @/GeneTgt$ mutations in high-grade prostate cancer before hormonal therapy . Androgen action is mediated through @GeneTgt$ androgen receptor @/GeneTgt$ ( @GeneTgt$ AR @/GeneTgt$ ) , which appears to undergo structural and functional alterations during prostate cancer ( CaP ) progression . @GeneTgt$ AR @/GeneTgt$ mutations have been infrequently reported in CaP before hormonal therapy , but in untreated , advanced tumors @GeneTgt$ AR @/GeneTgt$ mutations are suggested to be more common . To investigate the frequency of @GeneTgt$ AR @/GeneTgt$ mutations in aggressive CaP before hormonal therapy , we have analyzed @GeneTgt$ AR @/GeneTgt$ coding region for aberrations in 21 paraffin-embedded @DiseaseSrc$ prostate carcinoma @/DiseaseSrc$ samples ( 14 primary tumors , 7 metastases ) of poor histologic differentiation . Single-stranded conformational polymorphism and sequencing analyses revealed @GeneTgt$ AR @/GeneTgt$ missense mutations in 29 % ( 4/14 ) of the primary tumors and in one ( 14 % ) metastasis . Mutations resided in the transactivation domain and in the hinge region . One of the hinge region mutants , Ser646Phe , that was identified in a patient with short endocrine therapy response , exhibited a markedly increased transcriptional activity on single androgen response element-containing promoters . In conclusion , @GeneTgt$ AR @/GeneTgt$ mutations are frequent in high-grade CaP before initiation of hormonal therapy , and these mutations may play a role in poor therapy response and emergence of hormone-refractory CaP in some cases .	0|4 0|4 4 0|4 4 8 8 8 4 11 11 4 4 15 17 17 17 19 17|18|19 17|18|19 17|19 17|18|19 23 19|20 19 19|20 23 19 28 19 30 28 34 31 31 30 37 37 41 39 37 39 30 17 44|47 47 44|47 51 51 51 51 51 53 51 56 56 51 51 51 66 66 60 60 60 62|66 66 62|66 68 68 51 72 72 72 68 51 77 77 79 77 83 83|80 83 83|80 79 86 86 83 89 89 79 93 93 93 77 92|97 97 92|97 97 93 99 97 106 106 106 100|106 100|106 106 100|106 99 110 110 110 106 110 113 110 113 118 118 118 110 93 125 125 129 125 128 129 129 133|129 133 133|129 133 129 136 136 151 138 136 138 143 143 143 136 136 146 136 149 149 146 149 133 129 155 155 159 159 159 155 155 164 164 164 155 155 187 171 171 171 171 166 171 171 166 177 177 166 180 180 177 185 185 185 185 180 166 187 192 190 192 192 187 198 198 197 197 198 192 187 201 207 207 202|205 205 202|205 207 207 207 210 210 207 212 207 215 215 212 207 207 219 221 221 207 223 221 227 227 227 221 227 227 232 232 229 235 235 227 207	Association
14691288	Disease	Gene	D011471	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] @GeneTgt$ Androgen receptor @/GeneTgt$ mutations in high-grade @DiseaseSrc$ prostate cancer @/DiseaseSrc$ before hormonal therapy . Androgen action is mediated through @GeneTgt$ androgen receptor @/GeneTgt$ ( @GeneTgt$ AR @/GeneTgt$ ) , which appears to undergo structural and functional alterations during @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( CaP ) progression . @GeneTgt$ AR @/GeneTgt$ mutations have been infrequently reported in CaP before hormonal therapy , but in untreated , advanced tumors @GeneTgt$ AR @/GeneTgt$ mutations are suggested to be more common . To investigate the frequency of @GeneTgt$ AR @/GeneTgt$ mutations in aggressive CaP before hormonal therapy , we have analyzed @GeneTgt$ AR @/GeneTgt$ coding region for aberrations in 21 paraffin-embedded prostate carcinoma samples ( 14 primary tumors , 7 metastases ) of poor histologic differentiation . Single-stranded conformational polymorphism and sequencing analyses revealed @GeneTgt$ AR @/GeneTgt$ missense mutations in 29 % ( 4/14 ) of the primary tumors and in one ( 14 % ) metastasis . Mutations resided in the transactivation domain and in the hinge region . One of the hinge region mutants , Ser646Phe , that was identified in a patient with short endocrine therapy response , exhibited a markedly increased transcriptional activity on single androgen response element-containing promoters . In conclusion , @GeneTgt$ AR @/GeneTgt$ mutations are frequent in high-grade CaP before initiation of hormonal therapy , and these mutations may play a role in poor therapy response and emergence of hormone-refractory CaP in some cases .	0|4 0|4 4 0|4 4 7 7 4|7 4|7 4|7 4|7 12 12 4 4 17 19 19 19 21 19|20|21 19|20|21 19|21 19|20|21 25 21|22 21 21|22 25 21 30 21 32 30 36 33 33 32 38 34|44|38 34|44|38 44|38 34|44|38 42 38 42 32 19 48|51 51 48|51 55 55 55 55 55 57 55 60 60 55 55 55 70 70 64 64 64 66|70 70 66|70 72 72 55 76 76 76 72 55 81 81 83 81 87 87|84 87 87|84 83 90 90 87 93 93 83 97 97 97 81 96|101 101 96|101 101 97 103 101 109 109 109 109 109 103 113 113 113 109 113 116 113 116 121 121 121 113 97 127 127 131 127 130 131 131 135|131 135 135|131 135 131 138 138 153 140 138 140 145 145 145 138 138 148 138 151 151 148 151 135 131 157 157 161 161 161 157 157 166 166 166 157 157 189 173 173 173 173 168 173 173 168 179 179 168 182 182 179 187 187 187 187 182 168 189 194 192 194 194 189 200 200 199 199 200 194 189 203 209 209 204|207 207 204|207 209 209 209 212 212 209 214 209 217 217 214 209 209 221 223 223 209 225 223 229 229 229 223 229 229 234 234 231 237 237 229 209	Association
15617028	Disease	Gene	D011471	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] @GeneTgt$ Androgen receptor @/GeneTgt$ mutants detected in recurrent @DiseaseSrc$ prostate cancer @/DiseaseSrc$ exhibit diverse functional characteristics . BACKGROUND : Alterations in the function of @GeneTgt$ androgen receptor @/GeneTgt$ ( @GeneTgt$ AR @/GeneTgt$ ) and its signaling pathway may be responsible for the progression of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . The goal of the present study was to investigate the potential roles of @GeneTgt$ AR @/GeneTgt$ structural and functional alterations in the progression of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ , and the relationship between the structure and function of the @GeneTgt$ AR @/GeneTgt$ . METHODS : @GeneTgt$ AR @/GeneTgt$ gene in 58 @DiseaseSrc$ prostate cancer @/DiseaseSrc$ samples was examined for mutations using PCR-single strand conformation polymorphism ( SSCP ) analysis and DNA sequencing . Effects of mutations on the structure and function of @GeneTgt$ AR @/GeneTgt$ were investigated by androgen-binding assays and transactivation assays , respectively . RESULTS : Four novel somatic mutations ( G142V , D221H , E872Q , and M886I ) were identified from recurrent @DiseaseSrc$ prostate cancer @/DiseaseSrc$ samples . None of the @GeneTgt$ AR @/GeneTgt$ mutants differed from wild-type @GeneTgt$ AR @/GeneTgt$ ( wtAR ) in their abilities to bind the synthetic androgen methyltrienolone . However , these mutated @GeneTgt$ AR @/GeneTgt$ exhibited diverse functional characteristics as compared with wtAR . G142V and D221H showed increased responses to DHT . E872Q could be abnormally activated by 17beta-estradiol , progesterone , and cyproterone acetate ( CPA ) . Furthermore , E872Q and M886I presented increased responses to DHT in the presence of coactivators TIF-2 and CBP , but not p300 . On the other hand , although overexpression of corepressors N-CoR and SMRT could result in evident inhibition on DHT- or CPA-induced transactivity of wtAR and the @GeneTgt$ AR @/GeneTgt$ mutants , N-CoR displayed stronger inhibitory effects on DHT-induced transactivity of the @GeneTgt$ AR @/GeneTgt$ mutants ( especially for E872Q and M886I ) than that of wtAR . To our knowledge , this is the first characterization of enhanced inhibitory effects of corepressors on the transactivity of the @GeneTgt$ AR @/GeneTgt$ mutants found in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . CONCLUSIONS : The data presented here demonstrate that @GeneTgt$ AR @/GeneTgt$ mutants found in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ had different functional alterations , which might play an important role in the progression of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ .	0|4 0|4 4 0|4 11 4 8 8 8|5 8|5 8|5 8|5 11 14 14 11 11 38 18 38 23 23 20 25 25|23|24 25|23|24 25|23 25|23|24 29 25|26 25 25|26 29 25 35 35 23 38 38 38 41 41 38 43 41|43|39 41|43|39 41|43 41|43|39 38 51 56 55 55 55 51 56 58 56 61 61 58 63 68|62 68 68|62 63 65 65 61 71 71 61 73 73|71 73|71 73|71 73|71 61 61 79 61 82 82 79 82 82 87 87 82|83 82 82|83 56 105 105 94|97 97 94|97 105 103 103 103|98 103|98 103 103|98 97 105 105 107 105 107 112 112 112 116 114 112 114 108 116 119 116 105 135 125 123 128 128 125 128 128 132 131|128 128 131|128 135 135 138 138 135 138 141 138 135 135 135 146 146 151 151 151 163 153 151 153 153 155 155 153 153 153 153 163 146 169 169 169|165 169|165 169 169|165 163 146 178 177 177 174|177 177 174|177 172 178 181 181 179|178 178 179|178 184 181 184 188 188 178 190 178 194 194 194 190 178 204 204 202 202 201|204 204 201|204 204 207 207 204 209 204 211 209 204 217 214 214 217 219 217 221 219 217 227 227 227 227 227 229 227 229 229 229 229 235 229 237 235 237 227 245 245 245 242 242 245 247 245 249 247 252 252 247 254 252 254 255 255 255 260 255 255 245 266 266 266 294 294 276 276 271 269 271 272 272 276 294 279 279 276 281 284 281 281 279 286 284 284 291 288|291 291 288|291 284 294 294 294 297 297 294 300 300 297 305 305 305|301 305 305|301 300 300 309 309 300 309 309 309 314 300 316 314 294 322 322 328 328 328 328 328 328 328 332 332 332 328 334 332 337 337 332 342 342 339|342 342 339|342 337 342 345 343|345 343|345 343|345 343|345 328 351 351 354 357 354 355 351 367 358|361 361 358|361 367 361 364 362|364 362|364 362|364 362|364 357 370 368 367 370 374 374 370 377 377 374 380 380 374 382 382|378|380 382|378|380 382|380 382|378|380 351	Association
16039774	Disease	Gene	D011471	6716	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ SRD5A2 @/GeneTgt$ ? [SEP] The 5alpha-reductase type II A49 T and V89L high-activity allelic variants are more common in men with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ compared with the general population . OBJECTIVES : To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II ( @GeneTgt$ SRD5A2 @/GeneTgt$ ) gene . MATERIALS AND METHODS : The @GeneTgt$ SRD5A2 @/GeneTgt$ polymorphisms A49 T , V89L and R227Q , the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( CaP ) ( n=89 ) , benign prostate hyperplasia ( n=45 ) and healthy military conscripts ( n=223 ) . RESULTS : The @GeneTgt$ SRD5A2 @/GeneTgt$ high-activity allele variants A49 T AT and V89L LL were more frequent in CaP-patients compared to general population , p=0.026 and p=0.05 , respectively . CaP progression was , however , independent of @GeneTgt$ SRD5A2 @/GeneTgt$ variants . In contrary , men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats . CONCLUSIONS : Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population . In our population , androgen receptor genotype affected CaP outcome .	6 6 6 6 6 14 6 6 11 11 14 14 14 14 16 14 18 17|18|14 17|18|14 18|14 17|18|14 14 25 25 25 21 14 28 28 31 28 31 35 35 31 37 35 41 41 41 37 43 41 48 48 48 48 43 48 58 58 58 58 55 54|58 58 54|58 58 48 28 61 61 61 61 68 68|65 68 68|65 88 70 88 70 70 70 70 70 79 79 79 70 79 70 70 70 86 86 70 88 61 90 88 92 92|90 92|90 92|90 92|90 96 92 96 99 92 99 92 104 104 92 106 104 106 92 111 111 92 113 111 113 61 118 118 125 125|120 125 125|120 125 125 134 128 128 125 128 128 128 134 134 118 136 134 140 140 140 134 140 140 142 142 140 140 118 150 153 153 153 155 153 155 159 156|159 159 156|159 155 155 163 168 168 168 167 165 168 171 171 168 173 171 176 176 173 179 179 173 182 182 173 168 184 184 193 188 186 193 191 193 193 184 198 198 198 198 193 201 201 198 201 204 201 206 198 198 211 211 211 207 184 215 215 220 220 219 219 220 220 222 220 220	Association
17336451	Disease	Gene	D011471	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the @GeneTgt$ androgen receptor @/GeneTgt$ . The mechanisms underlying @GeneTgt$ androgen receptor @/GeneTgt$ @GeneTgt$ (AR)-mediated @/GeneTgt$ progression of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ following androgen ablation have yet to be fully determined . On this basis we screened naturally occurring mutants of human @GeneTgt$ AR @/GeneTgt$ for hormone-independent activity using a yeast model system . An initial screen of 43 different mutants revealed that ARs having a Leu701His mutation ( @GeneTgt$ AR(L701H @/GeneTgt$ ) ) exhibited hormone-independent activation of a lacZ reporter gene . The @GeneTgt$ AR(L701H @/GeneTgt$ ) mutant bound dihydrotestosterone to a similar extent as did wild type @GeneTgt$ AR @/GeneTgt$ , although its ability to be induced by hormone for transactivation was reduced substantially . Subsequent studies focused on the dependence of @GeneTgt$ AR(L701H @/GeneTgt$ ) on molecular chaperones for folding to the active state . We found that @GeneTgt$ AR(L701H @/GeneTgt$ ) was highly dependent on Hsp90 for its hormone-independent activation , suggesting that this chaperone functions in @GeneTgt$ AR(L701H @/GeneTgt$ ) folding . However , the mutant did not respond specifically to increased levels of FKBP52 , suggesting that this chaperone functions at the hormone-dependent activation stage in the folding process . Further studies of @GeneTgt$ AR(L701H @/GeneTgt$ ) in PC3 cells suggested that this mutant is prohibited from hormone-independent transactivation in mammalian cells . However , basal expression of a reporter gene by @GeneTgt$ AR(L701H @/GeneTgt$ ) was not impaired by the presence of 17-allylamino-17-demethoxygeldanamycin as was wild type @GeneTgt$ AR @/GeneTgt$ , suggesting differential interactions of these receptors with molecular chaperones in animal cells .	1 3 1 5 1 9 9 9 1 12 12 9|11|12 9|11|12 9|12 9|11|12 1 18 33 18 25|19 25|19 25 25|19 25|20 25 25|20 19 27 25|27|23 25|27|23 25|27 25|27|23 32 32 25 33 33 38 38 38 33 33 45 45 47 47 47 49 50 47 53 53 50|52 50 50|52 57 57 50 57 62 62 62 58 47 67 67 72 71 71 71 67 72 84 84 74 78 78 75 80 78|79 78 78|79 80 80 72 86 84 91 91 91 91 86 72 95 94|99 99 94|99 95 99 99 99 104 104 104 99 106 99 109 109 106|107 106 106|107 99 123 114 123 117 117 114 119 117 121 117 123 99 123 99 129 130 130 133 133 130 135 133|134 133 133|134 135 140 140 133 142 130 146 146 146 142 130 150 150 157 157|151 157 157|151 152 157 157 150 159 157 163 163 163 157 157 157 174 169 169 174 171 169 169 169 171 165 150 184 184 181 184 184 184 184 184 188 188 184 190 188 184 184 196 195 196 192 201 201 201 201 196 205 205 205 201 184 208 216 210 208|209 208 208|209 210 215 215 208 216 221 219 221 221 216 224 224 221 227 227 224 216 244 244 233 244 237 237 237 233 239 238|233 233 238|233 233 244 244 244 247 247 244 249 247 254 254 254 254 244|252 244 244|252 244 244 259 257 262 262 259 265 265 259 268 268 259 244	Association
12856637	Disease	Gene	D011471	324	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ APC @/GeneTgt$ ? [SEP] Elevated serum triiodothyronine ( t3 ) in Ashkenazi Jewish @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients carrying the I1307k allele of the @GeneTgt$ APC ( adenopolyposis coli ) @/GeneTgt$ gene . PURPOSE : The risk of developing any cancer in carriers of the I1307 K mutation of the adenopolyposis coli ( @GeneTgt$ APC @/GeneTgt$ ) gene is significantly increased ( odds ratio 1.5 , P = 0.01 ) . One of the cancers associated with the I1307 K mutation is @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( odds ratio 2.0 , P = 0.14 ) . Also , there is an association of @GeneTgt$ APC @/GeneTgt$ mutations with thyroid cancer . In this study , we measured triiodothyronine ( t3 ) levels in Ashkenazi Jewish @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients , with and without the I1307 K mutation of the @GeneTgt$ APC @/GeneTgt$ gene . MATERIALS AND METHODS : Participants in our study were found through urology and radiation oncology clinics in 1999 and 2000 . All eligible patients were asked to take part . All patients had been initially diagnosed on the basis of rising PSA or abnormal physical examination . Histological confirmation of diagnosis was obtained for all subjects . Ethnic background was confirmed for all subjects by self-report or interview . The I1307 K allele of the @GeneTgt$ APC @/GeneTgt$ gene was detected by amplification of DNA isolated from peripheral blood according to standard polymerase chain reaction ( PCR ) and dot blot procedures . Serum t3 level was determined by fluorescent immunoassay with a standard , commercially available instrument . RESULTS : We studied 77 patients . The youngest patient was 46 , the oldest 88 , average age 67 + /- 7.2 ( mean + /- SD ) . Eleven males carrying the APCI 1307 K allele had significantly higher serum t3 levels than 66 males carrying the wild type allele . There were no homozygotes for the I1307 K allele . None of the males had a t3 level that was above the normal range for our laboratory ( 137 ng/dl ) . CONCLUSIONS : Our findings of increased serum t3 level with the @GeneTgt$ APC @/GeneTgt$ I1307 K allele in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients is not surprising , given the mitogenic potential of t3 . Further studies may clarify whether t3 elevation is the mechanism whereby @GeneTgt$ APC @/GeneTgt$ gene mutations increase the risk of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ , or whether other pathophysiologic abnormalities are involved .	3 3 3 5 3 5 13 13 13 9|13 9|13 13 9|13 3 13 17 17 14 26 26 17|26|20 17|26|20 17|26|20 17|26|20 17|26|20 26|20 17|26|20 17 3 30 30 33 56 35 33 37 35 39 37 44 44 44 44 39 53 53 53 53 53 53|49 53 53|49 53 44 56 56 30 59 59 56 59 59 63 59 63 59 56 79 71 71 68 71 77 77 77 77 72 79 78|79 78|79 79 78|79 84 84 79 84 88 88 84 88 84 79 96 96 96 96 98 96 102 102|99 102 102|99 98 105 105 98 96 110 110 113 113 113 113 118 116 114 116 113 125 125 125 125|121 125|121 125 125|121 118 125 133 127 133 133 133 133 125 138 138 133|138 138 133|138 133 113 142 142 142 151 151 149 149 146 151 142 153 157 153 153 157 151 159 151 159 159 151 165 165 167 167 167 169 167 169 167 173 177 177 177 177 177 180 180 177 183 183 180 183 187 187 183 177 190 194 192 190 194 194 197 197 194 194 200 202 202 202 205 205 202 207 202 207 207 202 214 214 214 221 219 219 219|216 219 219|216 214 221 221 223 221 225 223 225 229 229 226 235 230 235 235 235 226 237 235 237 235 242 242 235 221 247 247 249 249 249 252 252 249 259 255 259 259 258 259 252 249 261 261 264 261 266 264 261 270 270 272 272 272 272 275 272 275 275 279 275 279 275 275 275 285 275 285 288 285 275 272 292 299 292 298 298 298 298 293 299 301 304 304 304 299 307 307 304 307 312 312 312 308 299 315 315 317 315 322 322 322 322 317 315 328 327 327 324 328 331 331 328 337 337 337 337 337 331 340 340 337 343 343 337 343 328 346 346 349 369 354 354 354 354 349 361 361 361|356 361 361|356 361 361 354 366 361|366 361|366 366 361|366 361 369 369 346 369 374 374 374 369 376 374 369 381 383 383 383 389 386 389 389 389 383 395 390|394 394 390|394 394 395 389 397 395 399 397|399 397|399 397|399 397|399 395 395 409 407 407 409 409 395 383	Association
18565893	Disease	Gene	D008545	472	True	0	What is [EMU_PC] between @DiseaseSrc$ melanoma @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for @DiseaseSrc$ melanoma @/DiseaseSrc$ , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 166|161 161 166|161 168 175 174 174 175 168 175 179 179 175 175 183 183 175 183 183 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
18565893	Disease	Gene	D001943	472	True	0	What is [EMU_PC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 72 69|72 69|72 69|72 69|72 64 64 81 81 81 81 64 85 85 85 81 52 90 90 90 95 95 90 97 95 102 102 102 102 97 105 105 97 105 109 109 105 95 112 114 114 95 114 95 135 117 120 117 122 120 127 127|123 127 127|123 127 122 127 127 135 135 134 134 131 135 139 139 139 135 139 142 149 149 149 149 149 148 149 117 149 153 153 149 153 156 156|153|154 156|153|154 156|153 156|153|154 156 164 163 163 164 135 164 168 168 164 168 171 164 171 177 176 176 177 171 177 181 181 177 177 185 185 177 185 185 192 191 191 192 171 192 196 196 192 196 199 171 203 203 203 199 135 208 208 210 208 215 215|211 215 215|211 215 210 215 215 223 223 222 222 223 208 227 227 227 223 227 230 237 237 237 237 237 236 237 208 241 241 241 237 241 244 242|244|237 242|244|237 244|237 242|244|237 244 252 251 251 252 237 252 256 256 252 256 261 261 261 256 256 252 268 267 267 268 252 268 272 272 268 272 275 268 278 278 275 208 282 290 283|287 287 283|287 287 290 290 290 282 292 290 294 292 290 295 298 298|295|296 298|295|296 298|295 298|295|296 304 304 304 290 290 309 309 309 290 312 312 309 320 317|310 317 317|310 317 320 320 320 309 324 324 324 320 328 328 328 324 282 335 335 344 337 335 344 344 342 342 339 344 344 346 344 346 347 350 346 344	Association
18565893	Disease	Gene	D011471	472	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 161 168 174 173 173 174 168 174 178 178 174 174 181 179|181|174 179|181|174 181|174 179|181|174 181 181 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
16835864	Disease	Gene	D011471	11200	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ CHEK2 @/GeneTgt$ ? [SEP] Characterization of @GeneTgt$ CHEK2 @/GeneTgt$ mutations in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . The @GeneTgt$ checkpoint kinase 2 @/GeneTgt$ ( @GeneTgt$ CHEK2 @/GeneTgt$ , also known as @GeneTgt$ CHK2 @/GeneTgt$ ) is a tumor suppressor that participates in the DNA damage-signaling pathway . It is phosphorylated and activated following DNA damage , resulting in cell cycle arrest and apoptosis . Previously , we reported germline @GeneTgt$ CHEK2 @/GeneTgt$ mutations in patients with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . In this study , we have identified two novel somatic @GeneTgt$ CHEK2 @/GeneTgt$ mutations , c.349A > G ( p. R117 G ) and c.967A > C ( p. E321 K ) , in @DiseaseSrc$ prostate tumor @/DiseaseSrc$ specimens and investigated the functions of these mutants in vivo . We have shown that most of the germline @GeneTgt$ CHEK2 @/GeneTgt$ mutations and one somatic mutation ( p. R117 G ) within FHA domain have modestly reduced @GeneTgt$ CHEK2 @/GeneTgt$ kinase activity in comparison with wild-type @GeneTgt$ CHEK2 @/GeneTgt$ while the other somatic mutation ( p. E321 K ) within the kinase domain of @GeneTgt$ CHEK2 @/GeneTgt$ totally abolished @GeneTgt$ CHEK2 @/GeneTgt$ kinase activity . Given that several clinical @GeneTgt$ CHEK2 @/GeneTgt$ mutations reside in the Forkhead-associated ( FHA ) domain , we further generated a series of missense mutations within this domain and demonstrated the requirement of an intact FHA domain for the full activation of @GeneTgt$ CHEK2 @/GeneTgt$ . Taken together , these results provide evidence that both germline and somatic @GeneTgt$ CHEK2 @/GeneTgt$ mutations identified in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ may contribute to the development of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ through the reduction of @GeneTgt$ CHEK2 @/GeneTgt$ activation in response to DNA damage and/or oncogenic stress .	1 5 2|5 5 2|5 1 7 1|5|7 1|5|7 1|7 1|5|7 1 14 13|14|31 13|14|31 13|14|31 14|31 13|14|31 19 14|15 14 14|15 19 23 14 25 20|23 23 20|23 14 31 31 31 31 33 31 38 38 38 38 33 31 45 45 45 45 45 50 50 47 45 45 56 56 56 52 56 56 45 63 63 63 63 67 67|64 67 67|64 63 69 67 71 69|71 69|71 69|71 69|71 63 79 79 83 83 83 83 83 89 89 89 86|89 89 86|89 83 83 83 91 92 97 97 97 93 97 91 91 106 106 106 106 106 100 106 91 113 108|113 108|113 113 108|113 91 83 83 117 115 120 120 117 122 115 83 128 128 128 151 151 136 136 136 133|136 136 133|136 130 130 140 140 130 144 144 144 140 144 148 148 140 151 151 128 150|155 155 150|155 155 151 157 151 160 160 157 157 157 180 166 166 166 180 170 170 170 166 170 175 175 175 166 177 173|175 175 173|175 180 151 184|176 184 184|176 184 180 128 198 198 197 197 194|197 197 194|197 198 209 205 205 205 205 205 205 198 209 209 209 209 211 209 214 214 211 217 217 211 209 209 221 219 226 226 226 226 221 230 230 230 221 232 230 230 230 209 242 237 242 241 242 242 242 252 246 252 246 251 248|251 251 248|251 246 243 254 252|254 252|254 252|254 252|254 258 242 261 261 258 263 261|263|259 261|263|259 261|263 261|263|259 268 268 261 272 264|272 272 264|272 268 274 268 277 277 274 277 280 277 242	Association
16741917	Disease	Gene	D011472	7157	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate carcinoma @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] The DU145 human @DiseaseSrc$ prostate carcinoma @/DiseaseSrc$ cell line harbors a temperature-sensitive allele of @GeneTgt$ p53 @/GeneTgt$ . BACKGROUND : Some nuances of mutant and wild-type @GeneTgt$ p53 @/GeneTgt$ activity have been uncovered utilizing temperature sensitive ( TS ) alleles . However , few human tumor derived cell lines possess a TS @GeneTgt$ p53 @/GeneTgt$ mutant . METHODS : The cell lines DU145 ( heterozygous @GeneTgt$ p53 @/GeneTgt$ , P223L , and V274F ) and PC3 ( @GeneTgt$ p53-null @/GeneTgt$ , where exogenous P223L and V274F were introduced individually or in combination ) were examined for TS @GeneTgt$ p53 @/GeneTgt$ activity as revealed by reporter construct and target gene activation . RESULTS : TS @GeneTgt$ p53 @/GeneTgt$ function was observed in DU145 and expression of the P223L allele in PC3 conferred a TS @GeneTgt$ p53 @/GeneTgt$ profile . Activation of p21Waf1 demonstrated that P223L TS activity may have been influenced by cellular context . CONCLUSIONS : The DU145 cell line harbors a TS mutant of @GeneTgt$ p53 @/GeneTgt$ and , in addition to being a widely used model of human @DiseaseSrc$ prostate carcinoma @/DiseaseSrc$ , may also reveal new insights into @GeneTgt$ p53 @/GeneTgt$ function due to the unique transcriptional properties of its TS phenotype .	8 8 8 8|3 8|3 8 8|3 8 9 9 12 12 9 14 11|12 12 11|12 9 19 19 22 32 24 22 24 24 26|29 29 26|29 24 32 32 19 32 39 34 37 35 37 33 19 47 47 46 46 47 47 49 50 47 55 55 52|55 55 52|55 50 47 93 93 62 62 93 62 66 66 65|63 63 65|63 66 66 69 66 66 66 63 63 77 75 75 75 77 86 82 86 82 82 86 77 88 86 90 86 77 93 93 98 98 98|93 98 98|93 93 100 93 103 103 100 103 107 107 103 93 130 112 117 114|117 117 114|117 119 119 112 121 119 121 121 127 127 127 123 129 127 130 135 135 135|131 135 135|131 130 130 142 141 139 142 150 146 146 150 150 150 150 142 153 153 150 142 155 155 160 160 160 161 155 164 164 161 166 164|165 164 164|165 161 161 171 186 173 171 177 176 177 173 180 180 178|180|177 178|180|177 180|177 178|180|177 186 186 186 161 188 186 192 186|192 192 186|192 188 198 193 198 198 198 188 202 202 202 198 155	Association
17487399	Disease	Gene	D030321	7490	True	0	What is [EMU_PC] between @DiseaseSrc$ Denys-Drash syndrome @/DiseaseSrc$ and @GeneTgt$ WT1 @/GeneTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneTgt$ WT1 @/GeneTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneTgt$ WT1 @/GeneTgt$ transcriptional target genes in prostate cancer cells , we have established stably transfected LNCaP cell lines expressing either @GeneTgt$ WT1(A @/GeneTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneTgt$ WT1 @/GeneTgt$ likely contributes to kidney angiogenesis during development and @GeneTgt$ WT1 @/GeneTgt$ mutants such as DDS(R384W ) are associated with the @DiseaseSrc$ Denys-Drash syndrome @/DiseaseSrc$ ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneTgt$ WT1(A @/GeneTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP prostate cancer cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneTgt$ DDS-WT1 @/GeneTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneTgt$ WT1 @/GeneTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneTgt$ DDS-WT1 @/GeneTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP prostate cancer cells . However our observations are also consistent with wild-type @GeneTgt$ WT1(A @/GeneTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneTgt$ WT1 @/GeneTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneTgt$ WT1 @/GeneTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 36 23 28 28|23 28 28|23 28 28 21 32 32 32 28 36 36 36 36 38 41 41 41 36 41 44 42 42 42 41 36 51 51 51 36 51 36 36 56 36 36 61 65 64 64 61 65 76 70 70 70 76 72 70 72 76 76 65 80 80 80 76 65 89 84 82 86 82|85 82 82|85 89 89 92 92 89 94 92 94 94 94 94 94 101 99 98 98 104 89 107 107 107|104 107|104 107|104 107|104 111 107 111 107 107 117 117 114 89 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 187 187 179 162 190 195 193 193 190 195 195 199 199 199 195 208 208 204 204 201 207 207 201 199 212 212 212 208 216 216 216 212 216 216 195 222 222 226 225 225 222 226 230 227|230 230 227|230 226 232 230 236 236 236 230 239 239 236 226 243 245 245 245 247 245 250 250 247 253 253 250 256 256 253 256 245 260 245 262 263 260 267 267 267 260 245 271 271 281 273 271|272 271 271|272 273 273 273 273 273 281 281 286 286 286 286 281 281 291 291 291 281 296 294 296 296 291 281 300 301 301 306 306|302 306 306|302 306 301 308 306 310 308 308 308 314 312 319 319 319 319 312 301 327 324 327 327 327 327 330 330 329|327 327 329|327 330 327 335 338 335 335 333 342 341 342 338 345 345 333 347 345 327 351 363 354 354 351 356 351|355 351 351|355 356 356 361 359 351 363 366 366 363 368 366 366 366 375 372 375 372 372 366 363	Association
17487399	Disease	Gene	D011471	7490	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ WT1 @/GeneTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneTgt$ WT1 @/GeneTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneTgt$ WT1 @/GeneTgt$ transcriptional target genes in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells , we have established stably transfected LNCaP cell lines expressing either @GeneTgt$ WT1(A @/GeneTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneTgt$ WT1 @/GeneTgt$ likely contributes to kidney angiogenesis during development and @GeneTgt$ WT1 @/GeneTgt$ mutants such as DDS(R384W ) are associated with the Denys-Drash syndrome ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneTgt$ WT1(A @/GeneTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneTgt$ DDS-WT1 @/GeneTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneTgt$ WT1 @/GeneTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneTgt$ DDS-WT1 @/GeneTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells . However our observations are also consistent with wild-type @GeneTgt$ WT1(A @/GeneTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneTgt$ WT1 @/GeneTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneTgt$ WT1 @/GeneTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 37 23 28 28|23 28 28|23 28 28 21 33 28|33 28|33 33 28|33 28 37 37 37 37 39 42 42 42 37 42 45 43|41 43 43|41 42 37 52 52 52 37 52 37 37 57 37 37 63 67 66 66 63 67 78 72 72 72 78 74 72 74 78 78 67 82 82 82 78 67 91 86 84 88 84|87 84 84|87 91 91 94 94 91 96 94 96 96 96 96 96 103 101 100 100 106 91 110 110 110 106 112 110 112 110 110 118 118 115 91 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 184|188 184|188 188 184|188 179 162 192 197 195 195 192 197 197 201 201 201 197 210 210 206 206 203 209 209 203 201 214 214 214 210 218 218 218 214 218 218 197 224 224 228 227 227 224 228 232 229|232 232 229|232 228 234 232 238 238 238 232 241 241 238 228 245 247 247 247 249 247 252 252 249 255 255 252 258 258 255 258 247 262 247 264 265 262 269 269 269 262 247 273 273 283 275 273|274 273 273|274 275 275 275 275 275 283 283 288 288 288 288 283 283 293 293 293 283 298 296 298 298 293 283 302 303 303 308 308|304 308 308|304 308 303 310 308 312 310 310 310 316 314 322 322 317|322 317|322 322 317|322 314 303 331 328 331 331 331 331 334 334 333|331 331 333|331 334 331 339 342 339 339 337 346 345 346 342 349 349 337 351 349 331 355 367 358 358 355 360 355|359 355 355|359 360 360 365 363 355 367 370 370 367 372 370 370 370 379 376 379 376 376 370 367	Association
16941491	Disease	Gene	D011471	7157	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Unique substitution of CHEK2 and @GeneTgt$ TP53 @/GeneTgt$ mutations implicated in @DiseaseSrc$ primary prostate tumors @/DiseaseSrc$ and cancer cell lines . Genetic defects in CHEK2 and @GeneTgt$ TP53 @/GeneTgt$ have been implicated in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ development . However , the interaction of these two genes in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ tumorigenesis has not been investigated . We previously described 11 CHEK2 mutations in a group of 84 primary @DiseaseSrc$ prostate tumors @/DiseaseSrc$ . In this report , we screened the same group of tumors for @GeneTgt$ TP53 @/GeneTgt$ mutations and revealed nine somatic and two germline mutations . One germline @GeneTgt$ TP53 @/GeneTgt$ mutation ( c.408A > T/p . Gln136His ) and two somatic mutations ( c.1022 T > G/p . Phe341Cys and c.108 - 109ins22/p . His37fsX13 ) are novel to human cancer . More interestingly , CHEK2 and @GeneTgt$ TP53 @/GeneTgt$ mutations were observed to be mutually substituted in these tumors . Analysis of five commonly used @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cell lines revealed that four cell lines harboring @GeneTgt$ TP53 @/GeneTgt$ mutations carry no CHEK2 mutation while the only cell line ( LNCaP ) carrying wild-type @GeneTgt$ TP53 @/GeneTgt$ harbors a CHEK2 mutation . The novel CHEK2 mutation ( c.1160C > T/p . Thr387Asn ) identified in LNCaP cells changes amino acid Thr387 to Asn which has been shown to impair CHEK2 autophosphorylation and activation . Our data suggest that the CHEK2 and @GeneTgt$ TP53 @/GeneTgt$ mutations can substitute each other in at least 25 % ( 21/84 ) of @DiseaseSrc$ prostate cancers @/DiseaseSrc$ and that DNA damage-signaling pathway plays an important role in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ tumorigenesis .	2 2 4 2 4 4|5 4 4|5 4 2 11 9|11 9|11 9|11 9|11 9|11 11 18 18 11 2 23 31 25 23 25 25|26 25 25|26 31 31 31 36 31|36 31|36 36 31|36 31 31 56 56 43 56 47 47 47 43 52 48|52 48|52 52 48|52 43 56 56 56 56 56 61 61 61 64 64 61 67 67 61 71 71 71 67|70|71 67|70|71 67|71 67|70|71 61 78 78 81 81 81 81 84 84 81 86 84 90 87|90 90 87|90 86 81 81 94 92 94 98 98 94 81 105 105 102|105 105 102|105 105 107 105 107 107 107 111 111 111 116 116 111 119 119 116 121 119 111 123 123 123 127 123 123 132 129 132 132 135 135 132 132 139 147 147 147 141 141|142 141 141|142 141 147 147 151 151 151 147 154 154 151 147 167 166 166 161 166 166|161 166|161 166 166|161 166 157 167 176 171 171 176 171 175|170 175 175|170 172 167 179 179 176 192 184 184 184 192 186 184 186 184 190 188|186 188 188|186 176 195 195 192 167 203 203 203 203 205 203 207 205 203 211 209 211 214 214 211 211 218 218 215 220 215 224 224 224 220 226 224 228 226 228 228 211 233 234 234 243 237 243 237 237|238 237 237|238 237 243 234 245 243 250 248 249 250 243 252 250 252 255 255|250|253 255|250|253 255|250 255|250|253 243 263 261 262 263 243 266 266 263 271 271|264 271|264 271 271|264 263 234	Association
16941491	Disease	Gene	D011471	11200	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ CHEK2 @/GeneTgt$ ? [SEP] Unique substitution of @GeneTgt$ CHEK2 @/GeneTgt$ and TP53 mutations implicated in @DiseaseSrc$ primary prostate tumors @/DiseaseSrc$ and cancer cell lines . Genetic defects in @GeneTgt$ CHEK2 @/GeneTgt$ and TP53 have been implicated in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ development . However , the interaction of these two genes in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ tumorigenesis has not been investigated . We previously described 11 @GeneTgt$ CHEK2 @/GeneTgt$ mutations in a group of 84 primary @DiseaseSrc$ prostate tumors @/DiseaseSrc$ . In this report , we screened the same group of tumors for TP53 mutations and revealed nine somatic and two germline mutations . One germline TP53 mutation ( c.408A > T/p . Gln136His ) and two somatic mutations ( c.1022 T > G/p . Phe341Cys and c.108 - 109ins22/p . His37fsX13 ) are novel to human cancer . More interestingly , @GeneTgt$ CHEK2 @/GeneTgt$ and TP53 mutations were observed to be mutually substituted in these tumors . Analysis of five commonly used @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cell lines revealed that four cell lines harboring TP53 mutations carry no @GeneTgt$ CHEK2 @/GeneTgt$ mutation while the only cell line ( LNCaP ) carrying wild-type TP53 harbors a @GeneTgt$ CHEK2 @/GeneTgt$ mutation . The novel @GeneTgt$ CHEK2 @/GeneTgt$ mutation ( c.1160C > T/p . Thr387Asn ) identified in LNCaP cells changes amino acid Thr387 to Asn which has been shown to impair @GeneTgt$ CHEK2 @/GeneTgt$ autophosphorylation and activation . Our data suggest that the @GeneTgt$ CHEK2 @/GeneTgt$ and TP53 mutations can substitute each other in at least 25 % ( 21/84 ) of @DiseaseSrc$ prostate cancers @/DiseaseSrc$ and that DNA damage-signaling pathway plays an important role in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ tumorigenesis .	2 2 4 2|3 2 2|3 4 4 4 2 11 9|11 9|11 9|11 9|11 9|11 11 18 18 11 2 23 31 25 23|24 23 23|24 25 25 31 31 31 36 31|36 31|36 36 31|36 31 31 56 56 43 56 47 47 47 43 52 48|52 48|52 52 48|52 43 56 56 56 56 56 61 61 61 65 62|65 65 62|65 61 68 68 61 72 72 72 68|70|72 68|70|72 68|72 68|70|72 61 80 80 83 83 83 83 86 86 83 88 86 91 91 88 83 83 95 93 95 99 99 95 83 104 104 104 104 106 104 106 106 106 110 110 110 115 115 110 118 118 115 120 118 110 122 122 122 126 122 122 131 128 131 131 134 134 131 131 137 145 145 145|138 145 145|138 139 139 139 145 145 149 149 149 145 152 152 149 145 165 164 164 159 164 164|159 164|159 164 164|159 164 155 165 173 169 169 173 169 172 170 165 177 172|177 177 172|177 173 189 182 182 182 189 184 182 184 182 188 186 173 193 187|193 193 187|193 189 165 202 202 199|202 202 199|202 202 204 202 206 204 202 210 208 210 213 213 210 210 217 217 214 219 214 223 223 223 219 225 223 224|228 228 224|228 225 228 228 210 235 236 236 245 239 245|238 245 245|238 239 239 239 245 236 247 245 252 250 251 252 245 254 252 254 257 257|252|255 257|252|255 257|252 257|252|255 245 265 263 264 265 245 268 268 265 273 273|266 273|266 273 273|266 265 236	Association
15714208	Disease	Gene	D011471	6041	True	0	What is [EMU_PC] between @DiseaseSrc$ impact on prostate cancer @/DiseaseSrc$ and @GeneTgt$ RNASEL @/GeneTgt$ ? [SEP] Mutation screening and association study of @GeneTgt$ RNASEL @/GeneTgt$ as a @DiseaseSrc$ prostate cancer @/DiseaseSrc$ susceptibility gene . To date , germline mutations have been found in three candidate genes for hereditary prostate cancer : ELAC2 at 17p11 , @GeneTgt$ RNASEL @/GeneTgt$ at 1q25 and MSR1 at 8p22 . @GeneTgt$ RNASEL @/GeneTgt$ , encoding the 2',5'-oligoadenylate-dependant @GeneTgt$ RNase L @/GeneTgt$ , seems to have rare mutations in different ethnicities , such as M1I in Afro-Americans , E265X in men of European descent and 471delAAAG in Ashkenazi Jews . In order to evaluate the relevance of @GeneTgt$ RNASEL @/GeneTgt$ in the German population , we sequenced its open reading frame to determine the spectrum and frequency of germline mutations . The screen included 303 affected men from 136 Caucasian families , of which 45 met the criteria for hereditary prostate cancer . Variants were analysed using a family-based association test , and genotyped in an additional 227 sporadic @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients and 207 controls . We identified only two sib pairs ( 1.4 % of our families ) cosegregating conspicuous @GeneTgt$ RNASEL @/GeneTgt$ variants with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ : the nonsense mutation E265X , and a new amino-acid substitution ( R400P ) of unknown functional relevance . Both alleles were also found at low frequencies ( 1.4 and 0.5 % , respectively ) in controls . No significant association of polymorphisms ( I97L , R462Q and D541E ) was observed , neither in case-control analyses nor by family-based association tests . In contrast to previous reports , our study does not suggest that common variants ( i.e. R462Q ) modify disease risk . Our results are not consistent with a high penetrance of deleterious @GeneTgt$ RNASEL @/GeneTgt$ mutations . Due to the low frequency of germline mutations present in our sample , @GeneTgt$ RNASEL @/GeneTgt$ does not have a significant @DiseaseSrc$ impact on prostate cancer @/DiseaseSrc$ susceptibility in the German population .	2 2 2 5 2 7 2|6 2 2|6 15 15 9|15 9|15 15 9|15 15 2 2 20 26 26 23 26 26 26 26 30 30 30 26 34 34 34 30 26 26 38 36 38 38|39 38 38|39 43 40 43 43 47 38 26 49|60 60 49|60 50 50 56 56 53|54|56 53|54|56 53|56 53|54|56 50 60 62 60 64 62 67 67 64 67 71 69 67 73 71 73 73 77 75 80 80 77 75 75 85 85 82 60 92 89 92 104 94 92 96 94|95 94 94|95 101 101 101 94 104 104 104 108 108 108 104 110 104 112 110 112 112 117 117 112 104 121 122 122 122 122 124 129 129 129 124 129 132 134 134 129 136 134 140 140 140 136 122 144 144 144 144 149 149 149 145 144 144 144 161 161 161 161 161 157|161 157|161 161 157|161 152 161 164 161 144 168 168 170 172 172 168 175 175 172 178 178 175 175 172 184 184|181 184 184|181 180 186 184|186 184|186 184|186 184|186 172 193 193 193 172 193 172 199 199 199 172 201 199 201 206 206 206 199 168 211 214 214 214 214 217 217 214 222 222 219 219 217 222 222 222 227 217 214 231 231 242 233 231 235 233 235 235 235 235 235 242 242 242 247 247 247 242 247 252 252 252 247 242 255 264 258 258 255 264 261 264 264 264 264 272 267 272 270 270 267 270 264 274 272 264 277 280 280 280 280 284 284 284 280 289 289 286|289 289 286|289 284 280 296 292 296 296 309 299 299 296 299 303 303 300 309 309|304 309 309|304 309 309 309 312 312 317|309|310 317|309|310 317|309|310 317|309|310 309|317 317|309|310 312 321 321 321 317 309	Association
16172807	Disease	Gene	D011471	5055	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ PAI2 @/GeneTgt$ ? [SEP] Nucleotide variations in genes encoding @GeneTgt$ plasminogen activator inhibitor-2 @/GeneTgt$ and serine proteinase inhibitor B10 associated with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . Genes encoding the serine proteinase inhibitor B family ( SERPINBs ) are mainly clustered on human chromosome 18 ( 18q21 ) . Several serpins are known to affect malignant phenotypes of tumor cells , so aberrant genetic variants in this molecular family are candidates for conferring susceptibility for risk of cancer . We investigated whether eight selected non-synonymous variations within SERPINB loci at 18q21 might be associated with risk of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in Japanese men . A case-control study involving 292 @DiseaseSrc$ prostate-cancer @/DiseaseSrc$ patients and 384 controls revealed significant differences in regard to distribution of four missense variations in genes encoding @GeneTgt$ plasminogen activator inhibitor 2 @/GeneTgt$ ( @GeneTgt$ PAI2 @/GeneTgt$ ) and SERPINB10 . The most significant association was detected for the N120D polymorphism in the @GeneTgt$ PAI2 @/GeneTgt$ gene ( P = 5.0 x 10(-5 ) ) ; men carrying the 120-N allele ( 120-N/N and 120-N/D genotypes ) carried a 2.4-fold increased risk of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( 95 % confidence interval 1.45 - 4.07 ) . Associations were also detected for three other missense polymorphisms in those two genes . Strong linkage disequilibrium in the region encompassing @GeneTgt$ PAI2 @/GeneTgt$ and SERPINB10 extended to about 50 kbp . The results suggested that missense variations in one or both of these genes confer important risks for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ , and may be themselves tumorigenic . Although confirmative replication studies on larger cohorts are awaited , clinical examination of these variations may become useful for identifying individuals at high risk for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ .	2 2 4 2 4 5|6 5|6 5|6 5|6 5|6 6 14 14 14 6 2 17 17|13|15 17|13|15 17|15 17|13|15 2 36 23 30 30 30 30 30 24 32 30 32 36 36 36 39 39 36 39 42 39 42 36 46 48 48 48 50 48 52 50 55 55 52 50 48 60 60 66 64 64 64 60 66 48 68 66 68 71 69 73 71 48 76 76 79 79 89 81 89 84 84 81 86 84 89 89 76 91 89 93 91|92|93 91|92|93 91|93 91|92|93 98 98 93 76 103 103 112 103 108 108|105 108 108|105 104 108 111 108 112 114 112 116 114 118 116 122 122 122 118 124 122 124 124|125|126 124|125|126 124|125|126 124|125|126 125|126 124|125|126 132 126 126 126 132 126 126 112 144 143 144 146 146 146 150 150 150 146 155 155 152|155 155 152|155 150 157 155 157 158 159 159 157 157 176 176 165 169 169 166 174 174 171 171 169 174 146 180 179 180 176 182 180|182 180|182 180|182 180|182 189 187 189 189 180 189 192 189 189 146 200 200 200 200 205 205 205 205 200 209 209 209 205 200 213 213 222 216 216 213 216 217 217 217 218 218 222 226 225 226 222 222 230 231 231 242 234 242 236 234 236 236 241 241 238 231 244 242 246 244|245|246 244|245|246 244|246 244|245|246 242 242 254 253 254 242 231 265 260 260 265 263 263 260 265 273 273 268 273 271 271 268 273 273 273 276 274 276 280 280 276 282 280|281|282 280|281|282 280|282 280|281|282 273	Association
14583476	Disease	Gene	D011471	6041	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ RNASEL @/GeneTgt$ ? [SEP] Effects of @GeneTgt$ RNase L @/GeneTgt$ mutations associated with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ on apoptosis induced by 2',5'-oligoadenylates . The @GeneTgt$ RNASEL @/GeneTgt$ gene , a strong candidate for the hereditary prostate cancer 1 allele ( HPC1 ) , encodes a single-stranded specific endoribonuclease involved in the antiviral actions of IFNs . @GeneTgt$ RNase L @/GeneTgt$ is activated enzymatically after binding to unusual 5'-phosphorylated , 2',5'-linked oligoadenylates ( 2 - 5A ) . Biostable phosphorothioate analogues of 2 - 5A were synthesized chemically and used to study the effects of naturally occurring mutations and polymorphisms in @GeneTgt$ RNASEL @/GeneTgt$ . The 2 - 5A analogues induced @GeneTgt$ RNase L @/GeneTgt$ activity and caused apoptosis in cultures of late-stage , metastatic human @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cell lines DU145 , PC3 , and LNCaP. However , DU145 and PC3 cells were more sensitive to 2 - 5A than LNCaP cells , which are heterozygous for an inactivating deletion mutation in @GeneTgt$ RNase L. @/GeneTgt$ The RNase activities of missense variants of human @GeneTgt$ RNase L @/GeneTgt$ were compared after expression in a mouse RNase L(-/- ) cell line . Several variants ( G59S , I97L , I220V , G296V , S322F , Y529C , and D541E ) produced similar levels of @GeneTgt$ RNase L @/GeneTgt$ activity as wild-type enzyme . In contrast , the R462Q variant , previously implicated in up to 13 % of unselected @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cases , bound 2 - 5A at wild-type levels but had a 3-fold decrease in RNase activity . The deficiency in @GeneTgt$ RNase L(R462Q @/GeneTgt$ ) activity was correlated with a reduction in its ability to dimerize into a catalytically active form . Furthermore , @GeneTgt$ RNase L(R462Q @/GeneTgt$ ) was deficient in causing apoptosis in response to 2 - 5A consistent with its possible role in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ development . Our findings support the notion that @GeneTgt$ RNASEL @/GeneTgt$ mutations and some variants allow tumor cells to escape a potent apoptotic pathway .	1 6 2|6 2|6 6 2|6 1 6 9 9|6|7 9|6|7 9|7 9|6|7 13 9 13 16 14 1 23 20|23 23 20|23 39 23 27 27 23 34 34 34 34 34 34 27 36 34 36 23 39 43 43 43 39 43 48 48 48 44 50 48 39 52|53|57 52|53|57 53|57 52|53|57 57 57 57 60 57 66 66 66 63 63 60 70 70 70 66 70 57 76 76 82 80 80 80 76 82 82 82 82 82 87 85 89 87 93 92 93 89 93 93 97 93|96 93 93|96 82 105 104 104 105 106 106 110|106 110|106 110 110|106 106 106 106 112 115 113 125 125 117 117 125 125|118 125|118 125 125|118 125 115 125 126 126 126 126 126 140 140 140 134 137 134 140 140 106 144 144 144 140 147 147 140 147 151 151 147 156 156 156 156 151 158 158|153|163 158|153|163 158|163 158|153|163 163 163 173 166 166 163 169 169 166|169|162 166|169|162 166|169 166|169|162 173 106 175 173 180 180 180 180 175 183 183 173 106 190 207 192 190 192 192 192 192 192 192 192 192 200 200 202 202 202 192 207 209 207 214 214|210 214|210 214 214|210 209 217 217 207 207 221 241 241 225 225 241 225 228 225 233 232 232 233 228 239 239 235|239 235|239 239 235|239 233 225 241 244 244 241 247 247 241 241 241 252 252 249 255 255 252 241 259 267 261 259|260|261 259|260|261 259|261 259|260|261 261 259 267 267 270 270 267 273 273 270 275 273 280 280 279 280 275 267 290 290 290|284|285 290|284|285 290|285 290|284|285 285 290 290 292 290 300 299 299 299 299 299 293 292 304 304 304 300 309 309|303 309|303 309 309|303 304 290 314 315 315 317 315 325 321|318 321 321|318 325 321 324 321 317 327 329 329 325 333 333 333 329 315	Association
15146458	Disease	Gene	D011471	23520	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ pp32r1 @/GeneTgt$ ? [SEP] Identification of a functional mutation in @GeneTgt$ pp32r1 @/GeneTgt$ ( @GeneTgt$ ANP32C @/GeneTgt$ ) . No mutations or polymorphisms have previously been reported in @GeneTgt$ pp32r1 @/GeneTgt$ ( @GeneTgt$ ANP32C @/GeneTgt$ ; GenBank : AF008216.1 ) . @GeneTgt$ pp32r1 @/GeneTgt$ is part of the highly conserved ANP32 family , some of whose members are associated with control of histone acetylation , mRNA stability , and specialized forms of apoptosis . Although 87.6 % identical at the protein level , @GeneTgt$ pp32r1 @/GeneTgt$ is functionally distinct from pp32 ( ANP32A ) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays . The present study found that @GeneTgt$ pp32r1 @/GeneTgt$ expression levels vary among human tumor cell lines , with the highest levels found in @DiseaseSrc$ prostatic adenocarcinoma @/DiseaseSrc$ cell lines . @GeneTgt$ pp32r1 @/GeneTgt$ also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions , human fibroblast cell lines , and several carcinoma cell lines . PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci , but additionally contain a g.4870T > C transversion mutation . The mutation results in a p. Tyr140His substitution , which lies in a functionally important region of the molecule . In the PC-3 @DiseaseSrc$ prostate cancer @/DiseaseSrc$ line , the mutation is either homozygous , or hemizygous accompanied by loss of heterozygosity . ACHN cells stably transfected with @GeneTgt$ pp32r1 @/GeneTgt$ containing this mutation showed a markedly increased rate of growth . The @GeneTgt$ pp32r1 @/GeneTgt$ mutation could thus be causally associated with the neoplastic growth properties of PC-3 , and be of potential clinical significance .	1 5 5 5 1 7 5|6 5 5|6 10 8|7 7 8|7 10 1 17 23 17 17 23 23 23 23 28 24|28 28 24|28 28 23|26 23 23|26 28 28 31 31 28 23 37|41 41 37|41 41 41 47 47 45 47 47 41 47 54 54 52 54 54 41 56 54 59 59 56 59 62 59 54 54 66 54 68 66 41 74 73 74 84 78 78 78 74 84 79|84 84 79|84 84 84 84 86 84 88 86 88 92 92 84 94 92 94 100 100 97 100 95 92 103 92 107 107 105 103 84 112 112 113 113 119 118|114 118 118|114 118 119 113 124 124 124 124 119 124 129 129 129 124 129 136 136|130 136|130 136 136|130 136 130 113 139|143 143 139|143 143 143 146 146 143 149 149 146 149 152 149 158 158 158 158 158 149 143 163 163 163 143 163 143 169 169 169 143 143 176 176 176 176 178 178 178 181 181 178 184 184 181 178 178 188 178 190 188 190 194 194 190 178 197 198 198 203 203 203 201 198 203 206 203 211 211 210 211 206 214 214 211 198 222 222 222 218|222 218|222 222 218|222 228 222 225 228 228 228 228 228 228 228 228 234 232 236 234 228 240 249 242 240 244 242|243 242 242|243 244 248 246 249 253 252 253 249 255 253 249 261 258|261 261 258|261 266 266 266 266 266 266 271 271 271 271 266 273 271 266 266 280 280 280 280 266 266	Association
17020975	Disease	Gene	D011471	6041	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ RNASEL @/GeneTgt$ ? [SEP] @GeneTgt$ RNASEL @/GeneTgt$ gene polymorphisms and the risk of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ : a meta-analysis . PURPOSE : Studies revealing conflicting results on the role of @GeneTgt$ RNASEL @/GeneTgt$ polymorphisms Glu265X , Arg462Gln , and Asp541Glu on @DiseaseSrc$ prostate cancer @/DiseaseSrc$ risk led us to perform a meta-analysis to investigate the association of these polymorphisms and @DiseaseSrc$ prostate cancer @/DiseaseSrc$ risk . EXPERIMENTAL DESIGN : Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords " @GeneTgt$ RNASEL @/GeneTgt$ gene AND @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . " For each study , odds ratio ( OR ) with 95 % confidence interval ( 95 % CI ) was calculated to estimate the gene effect . Pooled estimates of the OR were computed using the random effects model . RESULTS : Ten studies were included in the meta-analysis . The overall results suggested no major influence of these variants on @DiseaseSrc$ prostate cancer @/DiseaseSrc$ risk . However , analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu ( familial cases versus control : OR , 1.38 ; 95 % CI , 1.04 - 1.82 ; sporadic cases versus control : OR , 1.26 ; 95 % CI , 1.07 - 1.48 ; @DiseaseSrc$ prostate cancer @/DiseaseSrc$ versus control : OR , 1.29 ; 95 % CI , 1.12 - 1.48 ) and Asp/Glu + Glu/Glu ( familial cases versus control : OR , 1.37 ; 95 % CI , 1.10 - 1.70 ; sporadic cases versus control : OR , 1.24 ; 95 % CI , 1.07 - 1.44 ; @DiseaseSrc$ prostate cancer @/DiseaseSrc$ versus control : OR , 1.27 ; 95 % CI , 1.13 - 1.44 ) increased @DiseaseSrc$ prostate cancer @/DiseaseSrc$ risk in Caucasians , thus suggesting a dominant model for the Glu variant . CONCLUSIONS : Compared with the genotype Asp/Asp , the Glu variant at the Asp541Glu polymorphism @DiseaseSrc$ increases prostate cancer @/DiseaseSrc$ risk by < 2-fold in Caucasians , regardless of family history of the disease . This suggests that genuine genetic effects of this polymorphism may account for only a part of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ in the Caucasian population .	0|4 4 0|4 4 4 4 7 4 9 9|7 9|7 9|7 9|7 4 14 4 4 18 18 42 20 23 21 26 26 23 31 27|31 31 27|31 31 26 31 31 31 31 31 41 41|36 41|36 41 41|36 26 18 42 45 42 47 45 49 47 51 49 54 54 51 54 59|52|56 59|52|56 59|56 59|52|56 51 42 65 65 70 68 70 70 65 72 70 72 75 72 75 78 72 78 72 80 81 82|85 85 82|85 81 85 87|85 87|85 87|85 87|85 65 112 94 94 112 112 97 112 99 97 99 105 105 105 105 97 109 108 109 105 109 112 65 114 112 117 117 114 65 122 127 125 125 122 127 127 127 132 132 132 128 127 134 134 137 139 139 134 142 142 139 139 146 146 147 147 150 150 147 153 153 150 158 154|158 154|158 158 154|158 150 147 171 171 171 167 167 167 163 170 170 167 171 284 284 176 176 173 176 176 176 173 173 173 173 185 186 173 186 190 190 186 173 193 173 173 173 173 173 173 173 173 202 203 173 203 207 207 203 173 208|209|173 208|209|173 209|173 208|209|173 209 209 173 173 173 173 173 220 221 173 221 225 225 221 221 173 173 228 228 233 233 173 233 233 233 173 173 173 173 242 243 173 173 173 245 173 173 250 173 173 173 173 173 173 173 173 259 260 173 260 264 264 260 173 266|173|263 266|173|263 266|173 266|173|263 266 266 173 173 173 173 173 277 278 173 173 282 282 173 173 171 280|288 280|288 288 280|288 284 290 288 284 293 284 296 296 293 300 300 300 296 171 305 305 311 311 311 311 320 311 315 315 320 319 319 319 315 305|324|319 305|324|319 305|324|319 305|324 305|324|319 320 326 320 326 329 326 326 326 334 334 331 337 337 334 320 341 341 350 345 345 350 348 348 345 350 341 354 354 354 350 356 355|356|354 355|356|354 356|354 355|356|354 362 362 362 356 341	Association
11705864	Disease	Gene	D013274	999	True	0	What is [EMU_PC] between @DiseaseSrc$ gastric cancer @/DiseaseSrc$ and @GeneTgt$ CDH1 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ E-cadherin @/GeneTgt$ germ-line alterations with prostate cancer . In our recent cancer registry-based study , the incidence of @DiseaseSrc$ gastric carcinoma @/DiseaseSrc$ was increased up to 5-fold in male relatives of early-onset prostate cancer ( PCA ) patients . This association may reflect the influence of genetic factors predisposing individuals to both tumor types . Germ-line mutations of the @GeneTgt$ CDH1 @/GeneTgt$ gene at 16q have recently been associated with @DiseaseSrc$ familial gastric cancer @/DiseaseSrc$ . Furthermore , two genome-wide linkage studies of PCA recently reported positivity at 16q . We therefore identified families and individual patients with both gastric and PCA and investigated whether the @GeneTgt$ CDH1 @/GeneTgt$ gene mutations were involved in cancer predisposition in these cases . Fifteen of the 180 Finnish hereditary PCA families ( 8.3 % ) had one or more @DiseaseSrc$ gastric cancer @/DiseaseSrc$ cases . No truncating or splice site @GeneTgt$ CDH1 @/GeneTgt$ mutations were identified by PCR single-strand conformational polymorphism in these families or in eight individual patients who had both prostate and @DiseaseSrc$ gastric cancer @/DiseaseSrc$ . However , a novel S270A missense mutation in exon 6 of the @GeneTgt$ CDH1 @/GeneTgt$ gene was seen in a single family with four prostate and two @DiseaseSrc$ gastric cancers @/DiseaseSrc$ . A large-scale population-based survey indicated a higher prevalence of S270A among both familial PCA cases ( 3.3 % ; n = 120 ; P = 0.01 ) and unselected PCA patients ( 1.5 % ; n = 472 ; P = 0.12 ) as compared with blood donors serving as population controls ( 0.5 % ; n = 923 ) . We conclude that individual rare mutations and polymorphisms in the @GeneTgt$ CDH1 @/GeneTgt$ gene , such as S270A , may contribute to the onset of PCA and warrant further investigations in other populations . However , the @GeneTgt$ CDH1 @/GeneTgt$ gene does not appear to explain the link between prostate and @DiseaseSrc$ gastric cancer @/DiseaseSrc$ .	1 6 2|6 6 2|6 6 1 9 9 1 1 17 17 17 16 17 26 26 20 26 22 20|21|22 20|21|22 20|22 20|21|22 26 26 26 29 26 32 32 26 40 36 36 40 38 36 38 32 26 44 46 46 46 48 46 51 51 48 51 52 57 57 57 52 46 60 71 65 65 62|65 65 62|65 60 67 60 71 71 71 71 73 71|73 71|73 71|73 71|73 71|73 71 89 89 85 85 85 89 87 85 89 89 89 92 90 89 96 96 96 96 97 100 97 103 103 96 103 103 96 96 115 113 109|113 113 109|113 113 115 115 107 118 118 115 121 121 118 96 136 131 131 131 131 131 131 124 134 134 124 134 136 143 137 137 139|143 139|143 143 139|143 136 136 147 155 147 150 153 153|150 153 153|150 155 155 155 160 160 160 160 155 163 163 160 160 168 168 168 160 170 168 172 170 172 172 172 172 172 155 196 196 186 186 186 186 196 188 186 188 194 194 191|194 194 191|194 188 196 196 200 200 200 196 203 203 200 203 206 203|204|206 203|204|206 203|206 203|204|206 196 215 215 215 216 216 219 219 216 221 219 226 226 226 226 219 229 229 226 232 232 229 232 236 236 232 236 236 232 242 242 229 245 245 242 248 248 229 248 252 252 248 252 252 256 248 259 259 256 259 263 263 260 266 266 263 269 269 266 269 266 216 274 274 292 278 278 292 278 278 285 285 282|285 285 282|285 278 285 289 287 285 278 292 274 295 295 292 297 295 292 292 301 299 304 304 301 274 315 315 312 309|312 312 309|312 315 315 315 315 317 315 319 317 321 319 321 321 321 321 321 315	Association
11705864	Disease	Gene	D011471	999	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ CDH1 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ E-cadherin @/GeneTgt$ germ-line alterations with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . In our recent cancer registry-based study , the incidence of gastric carcinoma was increased up to 5-fold in male relatives of early-onset @DiseaseSrc$ prostate cancer @/DiseaseSrc$ ( PCA ) patients . This association may reflect the influence of genetic factors predisposing individuals to both tumor types . Germ-line mutations of the @GeneTgt$ CDH1 @/GeneTgt$ gene at 16q have recently been associated with familial gastric cancer . Furthermore , two genome-wide linkage studies of PCA recently reported positivity at 16q . We therefore identified families and individual patients with both gastric and PCA and investigated whether the @GeneTgt$ CDH1 @/GeneTgt$ gene mutations were involved in cancer predisposition in these cases . Fifteen of the 180 Finnish hereditary PCA families ( 8.3 % ) had one or more gastric cancer cases . No truncating or splice site @GeneTgt$ CDH1 @/GeneTgt$ mutations were identified by PCR single-strand conformational polymorphism in these families or in eight individual patients who had both prostate and gastric cancer . However , a novel S270A missense mutation in exon 6 of the @GeneTgt$ CDH1 @/GeneTgt$ gene was seen in a single family with four prostate and two gastric cancers . A large-scale population-based survey indicated a higher prevalence of S270A among both familial PCA cases ( 3.3 % ; n = 120 ; P = 0.01 ) and unselected PCA patients ( 1.5 % ; n = 472 ; P = 0.12 ) as compared with blood donors serving as population controls ( 0.5 % ; n = 923 ) . We conclude that individual rare mutations and polymorphisms in the @GeneTgt$ CDH1 @/GeneTgt$ gene , such as S270A , may contribute to the onset of PCA and warrant further investigations in other populations . However , the @GeneTgt$ CDH1 @/GeneTgt$ gene does not appear to explain the link between prostate and gastric cancer .	1 6 2|6 6 2|6 6 1 8 8|1|6 8|1|6 8|1 8|1|6 1 19 19 19 18 19 27 27 22 27 25 25 22 27 27 27 30 27 33 33 27 42 36 42|35|36 42|35|36 42|36 42|35|36 40 36 40 33 27 46 48 48 48 50 48 53 53 50 53 54 59 59 59 54 48 62 73 67 67 64|67 67 64|67 62 69 62 73 73 73 73 77 77 77 73 73 89 89 85 85 85 89 87 85 89 89 89 92 90 89 96 96 96 96 97 100 97 103 103 96 103 103 96 96 115 113 109|113 113 109|113 113 115 115 107 118 118 115 121 121 118 96 136 131 131 131 131 131 131 124 134 134 124 134 136 142 137 137 142 142 136 136 145 153 145 148 151 151|148 151 151|148 153 153 153 158 158 158 158 153 161 161 158 158 166 166 166 158 168 166 170 168 170 170 170 153 192 192 182 182 182 182 192 184 182 184 190 190 187|190 190 187|190 184 192 192 196 196 196 192 199 199 196 199 203 203 199 192 209 209 209 210 210 213 213 210 215 213 220 220 220 220 213 223 223 220 226 226 223 226 230 230 226 230 230 226 236 236 223 239 239 236 242 242 223 242 246 246 242 246 246 250 242 253 253 250 253 257 257 254 260 260 257 263 263 260 263 260 210 268 268 286 272 272 286 272 272 279 279 276|279 279 276|279 272 279 283 281 279 272 286 268 289 289 286 291 289 286 286 295 293 298 298 295 268 309 309 306 303|306 306 303|306 309 309 309 309 311 309 313 311 315 313 315 315 315 309	Association
18193092	Disease	Gene	D011471	1956	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] @GeneTgt$ Epidermal growth factor receptor @/GeneTgt$ activation in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ by three novel missense mutations . While @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( @GeneTgt$ EGFR @/GeneTgt$ ) dysregulation is known to play a critical role in prostate carcinogenesis , there has been no direct evidence indicating @GeneTgt$ EGFR @/GeneTgt$ mutations induce tumorigenesis in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . We previously identified four novel @GeneTgt$ EGFR @/GeneTgt$ somatic mutations in the @GeneTgt$ EGFR @/GeneTgt$ tyrosine kinase domain of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ patients : G735S , G796S , E804 G and R841 K . In this study , we investigated the oncogenic potential of these somatic mutations by establishing stable clonal NIH3T3 cells expressing these four mutations and WT EGFR to determine their ability to increase cell proliferation and invasion . In the absence of the EGF ligand , cell proliferation was readily increased in G735S , G796S and E804 G mutants compared to WT @GeneTgt$ EGFR @/GeneTgt$ . The addition of EGF ligand greatly increased cell growth and transforming ability of these same @GeneTgt$ EGFR @/GeneTgt$ mutants . Matrigel invasion assays showed enhanced invasion with G735S , G796S and E804 G mutants . Western blot analysis showed that these @GeneTgt$ EGFR @/GeneTgt$ mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase ( MAPK ) , signal transducer and activator of transcription 3 ( STAT3 ) and Akt pathways . Our findings demonstrate the oncogenic activation of three novel @GeneTgt$ EGFR @/GeneTgt$ somatic missense mutations in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . Molecules that regulate the mechanisms of their oncogenic activation represent novel targets for limiting tumor cell progression , and further elucidation of these mutations will have utility in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ treatment .	0|6 0|6 0|6 0|6 6 0|6 6 8 8|3|6 8|3|6 8|6 8|3|6 15 15 15 15 6 6 31 19|20|29 19|20|29 19|20|29 19|20|29 20|29 19|20|29 26 20|21 20 20|21 26 31 31 43 33 31 36 36 33 39 39 33 43 43 43 43 46 46 43 46 42|50 50 42|50 51 43 51 54 52|54|47 52|54|47 52|54 52|54|47 51 64 64 64 70 70 70|66 70 70|66 70 64 77 77 77|71 77 77|71 77 77 70 82 82|76 82|76 82 82|76 77 70 70 84 84 84 89 84 84 92 84 64 99 99 102 102 102 102 105 105 102 109 109 109 105 111 102 115 115 115 111 115 119 119 116 119 122 119 124 111 126 124 128 126 128 129 130 130 102 136 136 146 140 140 140 136 146 143 146 146 146 146 148 146 148 148 148 154 154 148 146 158 158 157|155 155 157|155 146 163 168 166 166 163 168 168 170 168 170 173 170 179 179 179 179|176 179 179|176 170 168 184 184 185 185 187 185 189 187 189 189 189 195 195 189 185 199 199 200 200 206 205 205|202 205 205|202 206 200 206 207 208 208 212 206 212 212 216 212 206 206 221 221 218 225 225 225 221 227 225 227 225 231 225 231 231 235 231 235 238 231 238 225 242 225 200 246 247 247 250 250 247 258 258 258 253|256 256 253|256 258 258 250 260 260|258|250 260|258|250 260|250 260|258|250 247 275 268 266 270 268 274 274 274 270 275 277 275 279 275 282 282 279 279 279 286 291 289 289 286 291 275 291 297 297|293 297|293 297 297|293 292 291	Association
